$103.15
0.44% day before yesterday
Nasdaq, Nov 28, 10:16 pm CET
ISIN
US09075V1026
Symbol
BNTX

BioNTech SE - ADR Stock price

$103.15
-1.88 1.79% 1M
+5.62 5.76% 6M
-10.80 9.48% YTD
-17.57 14.55% 1Y
-58.34 36.13% 3Y
-19.45 15.86% 5Y
+89.10 634.06% 10Y
+89.10 634.06% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
+0.45 0.44%
ISIN
US09075V1026
Symbol
BNTX
Industry

New AI Insights on BioNTech SE - ADR Insights AI Insights on BioNTech SE - ADR

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$24.7b
Enterprise Value
$8.1b
Net debt
positive
Cash
$16.8b
Shares outstanding
240.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
6.8 | 9.4
EV/Sales
2.2 | 3.1
EV/FCF
negative
P/B
1.2
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$3.7b | $2.6b
EBITDA
$-509.6m | $-1.7b
EBIT
$-954.2m | $-1.9b
Net Income
$-662.9m | $-1.3b
Free Cash Flow
$-1.3b
Growth (TTM | estimate)
Revenue
3.7% | -17.7%
EBITDA
22.1% | -65.3%
EBIT
-6.2% | -40.0%
Net Income
-22.4% | -73.8%
Free Cash Flow
-212.9%
Margin (TTM | estimate)
Gross
85.6%
EBITDA
-13.9% | -62.8%
EBIT
-26.1%
Net
-18.1% | -51.0%
Free Cash Flow
-34.7%
Financial Health
Equity Ratio
86.2%
Return on Equity
-3.4%
ROCE
-4.3%
ROIC
-19.4%
Debt/Equity
0.0
More
EPS
$-2.8
FCF per Share
$-5.3
Short interest
6.5%
Employees
7k
Rev per Employee
$470.0k
Show more

Is BioNTech SE - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

BioNTech SE - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a BioNTech SE - ADR forecast:

22x Buy
76%
7x Hold
24%

Analyst Opinions

29 Analysts have issued a BioNTech SE - ADR forecast:

Buy
76%
Hold
24%

Financial data from BioNTech SE - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
3,656 3,656
4% 4%
100%
- Direct Costs 526 526
21% 21%
14%
3,130 3,130
1% 1%
86%
- Selling and Administrative Expenses 625 625
9% 9%
17%
- Research and Development Expense 2,564 2,564
0% 0%
70%
-510 -510
22% 22%
-14%
- Depreciation and Amortization 445 445
82% 82%
12%
EBIT (Operating Income) EBIT -954 -954
6% 6%
-26%
Net Profit -663 -663
22% 22%
-18%

In millions USD.

Don't miss a Thing! We will send you all news about BioNTech SE - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioNTech SE - ADR Stock News

Neutral
GlobeNewsWire
3 days ago
MAINZ, Germany, November 26, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the approval of matters relating to the exchange offer (the “Offer”) for all outstanding shares of CureVac N.V. (Nasdaq: CVAC, “CureVac”) at the extraordinary general meeting (“EGM”) held by CureVac on November 25, 2025. At the EGM, over 99.16% of votes cast by CureVac shareholders were in favor of the pr...
Neutral
Seeking Alpha
11 days ago
BioNTech SE ( BNTX ) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies November 11, 2025 9:00 AM EST Company Participants Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Özlem Türeci - Co-Founder, Chief Medical Officer & Member of Management Board Ilhan Celik Michael Wenger Ramón Zapata-Gomez - CFO & Member of Management Board Dou...
Neutral
Reuters
15 days ago
Pfizer Inc said on Thursday said that it will sell 54.7% of its stake in German drugmaker BioNTech SE , over five years after both firms formed an alliance that yielded a vaccine to combat the deadly COVID-19 pandemic.
More BioNTech SE - ADR News

Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 for prostate cancer; BNT113 that is in Phase I clinical trial to treat HPV+ head and neck cancers; BNT114, which is in Phase I clinical trial for triple negative breast cancer; and BNT115 and BNT116 to treat other cancers, including ovarian cancer. It also develops individualized neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; next-generation checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has a collaboration with Pfizer Inc. to develop vaccines for the coronavirus using its mRNA-based drug development platform; and development and commercialization collaboration with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to advance a vaccine candidate BNT162 for the prevention of COVID-19 infections. The company was founded in 2008 and is headquartered in Mainz, Germany.

Head office Germany
CEO Ugur Sahin
Employees 6,772
Founded 2008
Website www.biontech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today